

Appln. No. 10/649,609
Amd. dated March 1, 2007
Reply to Office Action of October 18, 2006

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 (Currently amended). A method for treating infections, tumors and autoimmune and inflammatory diseases treatable with human fibroblast interferon (interferon-β), comprising administering an effective amount of a polyol-human fibroblast interferon ~~interferon-β~~-conjugate having a polyol moiety covalently bound to Cys¹⁷ of human fibroblast interferon ~~interferon-β~~ to a subject in need thereof.

2 (Original). The method according to claim 1, wherein said polyol moiety is a polyalkylene glycol moiety.

3 (Original). The method according to claim 2, wherein said polyalkylene glycol moiety is a polyethylene glycol (PEG) moiety.

4 (Currently amended). The method according to claim 1, wherein the polyol-human fibroblast interferon ~~interferon-β~~-conjugate has the same or higher ~~interferon-β activity antiviral and antiproliferative activity~~ as native human interferon-β fibroblast interferon.

Claims 5-22 (Cancelled).

23 (New). A method for treating multiple sclerosis, comprising administering an effective amount of a polyol-human

fibroblast interferon (interferon- β) conjugate having a polyol moiety covalently bound to Cys¹⁷ of human fibroblast interferon to a subject in need thereof.

24 (New). The method of claim 23, wherein said polyol moiety is a polyalkylene glycol moiety.

25 (New). The method of claim 24, wherein said polyalkylene glycol moiety is a polyethylene glcol (PEG) moiety.

26 (New). In a method for treating infections, tumors and autoimmune and inflammatory diseases treatable with human fibroblast interferon (interferon- β), which comprises administering an effective amount of human fibroblast interferon to a subject in need thereof, the improvement wherein the human fibroblast interferon is a polyol-human fibroblast interferon conjugate having a poly moiety covalently bound to Cys¹⁷ of human fibroblast interferon.

27 (New). The method of claim 26, wherein said polyol moiety is a polyalkylene glycol moiety.

28 (New). The method of claim 27, wherein said polyalkylene glycol moiety is a polyethylene glycol (PEG) moiety.